Rare Beyond Compare ...

How CMTC-OVM US Was Formed

In 2011, the Global CMTC-OVM US Organization was formed solely by US members. The documents were filed by an attorney to legally become a non-profit 501 (c) (3) charity organization; this was paid through a loan from one of our families.

From that point forward, the CMTC-OVM US Organization has been a private entity governed by no other organization. We operate by the guidance of a board of directors. And, all financial support is received through our members, donors, and fundraising projects.

Building Awareness

One of the best ways to build awareness, is to be in front of the public. Throughout the year, the Global CMTC-OVM US Organization is represented at various conferences across the United States and abroad.

Our goal is to attend more conferences to educate others about the organization, as well as to build awareness of the vascular malformations supported by the organization.

 image

Calendar

December 14, 2016 – CMTC-OVM US Board Meeting

May 6, 2017 – Canadian CMTC Foundation Conference

September 14 & 15, 2017 – Global Genes Rare Patient Advocacy Summit

October 16 & 17, 2017 – NORD Rare Disease & Orphan Products Summit

November 3, 2017 – CMTC-OVM NL Conference

November 10 & 11, 2017 – Family Medicine Education Consortium

stars-tiny

Genetic Research

The actual state of the research is that we are inviting participation from those with classic CMTC. The study involves providing a blood or saliva sample as well as a 3 mm diameter round skin biopsy. We plan to sequence both and look for differences. Thus far we have 2 participants from Canada and one from Holland, we need 2 more to begin.” ~Dr. Millan Patel

To participate in this study, consult your Vascular Anomalies Team or Dermatologist to schedule the biopsy and make arrangements for the specimens to be sent to Dr. Patel.

You may contact Dr. Patel and his collaborator directly:

Dr. Millan Patel

Dr. Anna Lehman

2016 Conference and Family Day Highlights

20160723_125337Once again, Family Day and the Annual Conference have come and gone; but, the excitement and the memories will continue as we plan for next year.

It can be hard to express the benefits of attending an annual conference. You find others created just like you or your child, make new friends, meet those you have communicated with on Facebook, and have the chance to be reacquainted with those from the past. When you watch children experience this… it becomes an emotional, fulfilling encounter in the world of rare diseases.

Click here to read the full report.

 

20160723_100256

 

 

stars-tiny

Our activities are aimed at the well-being of people who suffer from vascular malformations like CMTC ('Van Lohuizen syndrome') and to stimulate the scientific research of these afflictions. Become a Member
  • 2016 NORD Annual Conference

img_1302On October 16, 2016, Bec, her granddaughter Ellayna, and her son Jamey drove 7 hours through the mountains on a gorgeous fall day, arriving in Arlington, Virginia for the annual NORD Rare Diseases & Orphan Products Breakthrough Summit.

The summit began with a welcome from Peter Saltonstall, President and CEO of NORD. Following Peter’s welcome, we heard from Kristen Gray, Co-Founder of Charlotte and Gwenyth Gray Foundation. Kristen’s daughters, Charlotte and Gwenyth, suffer from Battons Disease, a rare genetically inherited disorder which belongs to a group of progressive degenerative neurometabolic disorders, known as the neuronal ceroid lipofuscinoses (NCLs). NCLs are characterized by genetic mutations which disrupt cells’ ability to dispose of wastes, resulting in the abnormal accumulation of certain proteins and lipids (fats) within the nerve cells of the brain and other tissues of the body, resulting in progressive neurological impairment including developmental regression, seizures, blindness, behavior changes and dementia. After the creation of the foundation and excessive fundraising, a clinical trial came to fruition and six children have been treated at Nationwide Children’s Hospital in Columbus, Ohio. As a result of this trial, Charlotte is now stable and Gwenyth is asymptomatic.

Dr. David Flanders, Medical Director American College of Medical Genetics spoke next about Telemedicine and Rare Diseases. Telemedicine is the use of telecommunication and information technology to provide clinical health care from a distance. It helps eliminate distance barriers and can improve access to medical services that would often not be consistently available in distant rural communities. In our case of rare vascular anomalies this would create access to specialists. Several weeks ago, Bec had already arranged an appointment with the VAC (vascular anomalies clinic) team at the Cleveland Clinic to discuss this very option. She will be meeting with the VAC team on November 14th. Please understand, we are in the beginning stages and will undoubtedly have legal and ethical stages to go through, including the process of medical licensure across state lines.

Prior to lunch on day one, we heard from a panel discussing the potential advances through genetic innovations such as whole exome sequencing and gene therapy. The Lunch and Learn Breakout Roundtables offered 20 different topics, we chose Optimal Use of Social Media by Patient Organizations. Each table had a moderator who kept the conversation going, as well as offered their experience in the table’s topic. Facebook is considered the platform used mostly by families searching for advocacy organizations and guidance. While Twitter is more focused toward a professional platform, where people can be connected with medical professionals and pharmaceutical companies.

Collaboration Across Boarders breakout session confirmed that rare diseases are a challenge in a sense of global public health. It is difficult for trials and research to cross boarders, as each country has laws governing the sharing of medical information and the process involved in research. Many countries recognize FDA approval, but if they choose to accept it is another factor. Day one concluded with presentations regarding the Challenges of Access and Reimbursement and the Landscape for Investment. These sessions focused on the idea of experience in the strategic design and delivery of programs that continuously improve patient access to pharmaceutical products and adherence to therapy.

Day two kicked off with a presentation regarding healthcare and the implications img_1305expected from the presidential election. Driving Progress Through Policy was addressed through the importance of state-based advocacy and a productive national outlook. The afternoon tracks covered Trending Topics from FDA, Strategies to Address Patient Challenges, and Breaking Down Barriers to Access.

Bec had the opportunity to connect with multiple people over the two days. Through the summit app, arranging meetings with other participants was a snap. Her first scheduled meeting was with Carrie Ostrea of Global Genes. They discussed ideas for outreach and spreading awareness for our organization and the diagnoses we support. Jaime Pacheco of PALS – Patient AirLift Services was meeting number two. Jaime explained that PALS has arranged nearly 11,000 flights since their creation, with approximately 200 flights per month. She also stated that they do not only arrange flights using general aviation, but when necessary can arrange commercial flights. Mary Dunkle – VP Educational Initiatives at NORD was next on the schedule. She and Bec are moving forward on developing their plan to educate nursing students across the country about how to care for rare disease patients. Yasmin Kiera of WEP Clinical contacted Bec for an appointment to discuss how her company could assist our members. Unfortunately, this will be something for the future, as they provide access to drug therapies and we’re not there just yet.

Also during the summit, Bec was asked to participate in two video projects. The first was an initiative NORD introduced to send to medical schools. The purpose is to educate medical students about rare diseases, and the frequency of misdiagnosed as well as undiagnosed patients. The second was by Rare Disease Communications – Rare Disease Report. They are a healthcare communications and media company focused on the rare disease community. Their goal is to raise awareness of rare diseases and orphan drugs so that patients will be diagnosed and treated more efficiently. Their flagship website (Rare Disease ReportTM) and various news sources are seen and shared by physicians, nurses, patients, patient advocates, scientists, and regulators, reaching over 80,000 sources.

The outcome of this summit for our organization was found to be the most beneficial and productive one we have ever attended. Although many topics addressed concepts that are far down the pipeline for us, we can be hopeful of an easier journey, as the pathway has been carved by those before us. But for now, the meetings and videos have a promising possibility of leading to wonderful opportunities for the CMTC-OVM US Organization.